Innoviva, Inc. (INVA)

Environment story

Innoviva discloses minimal direct environmental emissions data and has not published a formal net-zero commitment or target date. The company operates as a biopharmaceutical royalty and specialty therapeutics business with no disclosed Scope 1, Scope 2, or Scope 3 emissions inventory. No evidence of renewable energy procurement targets, carbon reduction initiatives, or environmental controversies appears in available filings. The company has not established measurable decarbonization infrastructure or published ESG sustainability reports. Environmental disclosure is substantially below industry practice for biopharmaceutical firms.

Social story

Innoviva employs 159 people as of December 31, 2025. The company does not disclose CEO-to-median-worker pay ratios, workforce diversity metrics, union standing, or documented labor relations issues in the 10-K filing. No strikes, union-suppression allegations, or NLRB complaints are evident. Diversity representation in executive and board leadership is not quantified. Supply-chain human-rights policies are not addressed in the filing. The company lacks published diversity, equity, and inclusion programs or civil-rights audit documentation. Labor practices and social commitments remain substantially undisclosed.

Governance story

Board independence percentage, share structure details, and annual lobbying expenditures are not disclosed in the 10-K filing. The company does not report dual-class voting structures or conflicts of interest. No evidence of active lobbying campaigns against climate or consumer-protection regulation appears in the filing. The company has not disclosed material antitrust, SEC enforcement actions, privacy fines, or consent decrees. No documented litigation against shareholder climate proposals exists. Governance reporting is minimal; standard disclosure metrics for board composition, political engagement, and regulatory proceedings are absent.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Innoviva, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Innoviva, Inc. in the app for interactive charts and portfolio building.

More in Healthcare